Unknown OBSERVATIONAL NCT04733131

Long-term Outcomes After Conversion to Belatacept

Long-term Outcomes After Conversion to a Belatacept-based Immunosuppression in Kidney Transplant

Sponsor: Paris Translational Research Center for Organ Transplantation

Conditions Drug Effect Prolonged Graft Loss Immunosuppression Kidney Transplant Failure and Rejection

Interventions Conversion to a belatacept regimen

Updated 4 times since 2021 Last updated: Jan 29, 2021 Started: Jan 1, 2004 Primary completion: Jun 30, 2021 Completion: Dec 31, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Drug Effect Prolonged and Graft Loss, this trial is ongoing. The trial is conducted by Paris Translational Research Center for Organ Transplantation and has accumulated 4 data snapshots since 2004. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Unknown
Jul 2024 — Sep 2024 [monthly]

Unknown

Status: Unknown Status → Unknown
Feb 2023 — Jul 2024 [monthly]

Unknown Status

Status: Active Not Recruiting → Unknown Status
Mar 2021 — Feb 2023 [monthly]

Active Not Recruiting

First recorded

Jan 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Paris Translational Research Center for Organ Transplantation

Data source: Paris Translational Research Center for Organ Transplantation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.